Elmas KASAP, İrem Nur GÖKBAYRAK ATAY, Ayhan Hilal GEZER

The Importance of Apoptosis in Cancer Development and Treatment

Cancer is one of the most important causes of death in our era. Multifactorial causes are involved in the formation of cancer. The reduction of apoptosis is one of these reasons. Failure to activate apoptosis pathways can lead to resistance to the current treatment approaches of cancers. A better understanding of the molecular events that regulate apoptosis in cancers and cancer therapy form the basis of a more rational approach to the development of molecular targeted therapies in the fight against cancer.

PDF

___

1. Cohen JJ. Apoptosis to be or not to be. Vol. 1. Postgraduate Syllabus (AA-AA-I); 1998. p. 1–19.
2. Sanmartín C, Plano D, Palop JA. Selenium compounds and apoptotic modulation: A new perspective in cancer therapy. Mini Rev Med Chem 2008;8(10):1020–31.
3. Baykara O. Current Modalities in Treatment of Cancer. Balikesir Saglik Bil Derg Cilt: 5 Sayı: 3; 2016.
4. Fadeel B, Orrenius S, Zhivotovsky B. Apoptosis in human disease: A new skin for the old ceremony? Biochem Biophys Res Commun 1999;266(3):699–717.
5. Cummings MC, Winterfold CM, Walker NI. Apoptosis. Am J Surg Pathal 1997;21(1):88–101.
6. Koff JL, Ramachandiran S, Bernal-Mizachi L. A time to kill: Targeting apoptosis in cancer. Int J Mol Sci 2015;16(2):2942–55.
7. Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 2004;1644(2–3):125–32.
8. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007;39(7–8):1462–75.
9. Barnhart BC, Alappat EC, Peter ME. The CD95 Type I/Type II model. Semin Immunol 2003;15(3):185–93.
10. Nitulescu GM, Draghici C, Olaru OT, Matei L, Loana A, Dragu LD, et al. Synthesis and apoptotic activity of new pyrazole derivatives in cancer cell lines. Bioorg Med Chem 2015;23(17):5799–808.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57–70.
12. Soini Y, Paakkö P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998;153(4):1043–9.
13. BenJilani KE, Gaillard JP, Petit F, Arnoult D, Roumier AS, Labalette M, et al. A suppressive effect of the adenovirus 5 protein E1B 55K on apoptosis induced by IL-3 deprivation and gamma-irradiation. Biol Cell 2002;94(2):77–89.
14. Mehmet H, Laurenzi VD, Stassi G, Walczak H. Programmed cell death in disease. In: Teaching Workshop on Apoptosis. 1st ed. İzmir: Dokuz Eylül University Institute of Health Sciences; 2006. p. 12–7.
15. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and baxgene expression in vitro and in vivo. Oncogene 1994;9(6):1799–805.
16. Vaux DL. Immunopathology of apoptosis introduction and overview. Springer Semin Immunopathol 1998;19(3):271–8.
17. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9(10):1002–11.
18. Sheng S, Zheng J, Cui S, Cui X, Qian Z. Complete remission of multiple lung metastases after ablation of hepatocellular carcinoma by transarterial infusion with the p53 gene. Anticancer Drugs 2015;26(2):227– 31.
19. Shen A, Liu S, Yu W, Deng H, Li Q. p53 gene therapy- based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. J Gastroenterol Hepatol 2015;30(11): 1651–6.
20. Israels LG, Israels ED. Apoptosis. Oncologist 1999;4(4):332–9.
21. Choen GM. Caspases: The executioners of apoptosis. Biochem J 1997;326(1):1–16.
22. Lee D, Scott AL, Jerry AL. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 2000;275(21):16007–14.
23. Kidd VJ, Lahti JM, Teitz T. Proteolytic regulation of apoptosis. Semin Cell Dev Biol 2000;11(3):191–201.
24. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: Processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Commun 2010;396(1):95–100.
25. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008;27(48):6252–75.
26. Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 2007;120(11):2344–52.
27. Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Overexpression of survivin initiates haematologic malignancies in vivo. Leukaemia 2010;24(11):1920–6.
28. Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, et al. Increased expression of inhibitor of apoptosis proteins, Survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 2009;35(6):1449–62.
29. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305(5684):626–9.
30. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, et al. Mannose 6-phosphate/insulin- like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000;103(3):491–500.
31. Reed JC. Proapoptotic multidomain Bcl-2/Baxfamily proteins: Mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006;13(8):1378–86.
32. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001;292(5517):727–30.
33. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001;15(12):1481–6.
34. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104(4):487–501.
35. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010;42(2):210–3.
36. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr Cancer Drug Targets 2008;8(1):37–46.
37. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O’Byrne K, et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 2009;16(10):1352–61.
38. Chen LY, Chen TH, Wen PY, Chou CH, Ying TH, Chang SP, et al. Differential expression of NUDT9 at different phases of the menstrual cycle and in different components of normal and neoplastic human endometrium. Taiwan J Obstet Gynecol 2009;48(2):96– 107.
39. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, et al. c-FLIP expression in colorectal carcinomas: Association with Fas/FasL expression and prognostic implications. Histopathology 2007;51(2):150–6.
40. Gao S, Wang H, Lee P, Melamed J, Li CX, Zhang F, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 2006;36(3):463–83.
41. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35(4):495–516.
42. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol 2001;127(1):20–6.
43. Makinand G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000;301(1):143–52.
44. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6(5):513–9.
45. Wong RS. Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res 2011;30(1):87.
46. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the Bax gene. Cancer Res 1999;59:2121–6.
47. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005;56:46–54.
48. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005;4(3):443–9.
49. Blagosklonny MV.Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 2002;16(4):455–62.
50. Thu HE, Hussain Z, Mohamed IN, Shuid AN. Eurycoma longifolia, A potential phytomedicine for the treatment of cancer: Evidence of p53-mediated apoptosis in cancerous cells. Curr Drug Targets 2018;19(10):1109–26.